- Home
- VSTM vs MAIA Comparison
VSTM vs MAIA Comparison
Compare VSTM & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VSTM
- MAIA
- Stock Information
- Founded
- VSTM 2010
- MAIA 2018
- Country
- VSTM United States
- MAIA United States
- Employees
- VSTM N/A
- MAIA N/A
- Industry
- VSTM Biotechnology: Pharmaceutical Preparations
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- VSTM Health Care
- MAIA Health Care
- Exchange
- VSTM Nasdaq
- MAIA Nasdaq
- Market Cap
- VSTM 132.0M
- MAIA 62.4M
- IPO Year
- VSTM 2012
- MAIA 2022
- Fundamental
- Price
- VSTM $3.88
- MAIA $2.82
- Analyst Decision
- VSTM Strong Buy
- MAIA
- Analyst Count
- VSTM 8
- MAIA 0
- Target Price
- VSTM $14.57
- MAIA N/A
- AVG Volume (30 Days)
- VSTM 1.1M
- MAIA 60.0K
- Earning Date
- VSTM 11-06-2024
- MAIA 11-05-2024
- Dividend Yield
- VSTM N/A
- MAIA N/A
- EPS Growth
- VSTM N/A
- MAIA N/A
- EPS
- VSTM N/A
- MAIA N/A
- Revenue
- VSTM $10,000,000.00
- MAIA N/A
- Revenue This Year
- VSTM N/A
- MAIA N/A
- Revenue Next Year
- VSTM $125.69
- MAIA N/A
- P/E Ratio
- VSTM N/A
- MAIA N/A
- Revenue Growth
- VSTM N/A
- MAIA N/A
- 52 Week Low
- VSTM $2.10
- MAIA $0.82
- 52 Week High
- VSTM $14.22
- MAIA $5.99
- Technical
- Relative Strength Index (RSI)
- VSTM 63.77
- MAIA 50.98
- Support Level
- VSTM $3.11
- MAIA $2.36
- Resistance Level
- VSTM $3.76
- MAIA $2.72
- Average True Range (ATR)
- VSTM 0.33
- MAIA 0.22
- MACD
- VSTM 0.04
- MAIA 0.02
- Stochastic Oscillator
- VSTM 94.26
- MAIA 72.28
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company. The company develops targeted immunotherapies for cancer. The company is an immune-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's program is THIO, a potential cancer telomere-targeting agent in clinical development for the treatment of telomerase-positive cancer cells.